Quality by Design–Applied Liquid Chromatography-Tandem Mass Spectrometry Determination of Enzalutamide Anti-Prostate Cancer Therapy Drug in Spiked Plasma Samples

Quality by Design–Applied Liquid Chromatography-Tandem Mass Spectrometry Determination of Enzalutamide Anti-Prostate Cancer Therapy Drug in Spiked Plasma Samples ASK Sankar School of Pharmaceutical Sciences, Vels University (VISTAS), Chennai, India Adhiparasakthi College of Pharmacy, Melmaruvathur, Tamilnadu, India Shanmugasundaram Palani School of Phamaceutical Sciences, Vels University, (VISTAS), Chennai, India Ravichandiran Velayudham National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, India

This research article presents the Quality by Design (QbD)–finalised conditions for a method that uses liquid chromatography-tandem mass spectrometry for the determination of concentration of enzalutamide (ENZ), an atypical anticancer drug, in a drug formulation and in spiked plasma samples. Critical process attributes (CPA) considered to be the influential parameters in separation, identification, and quantification processes by ultrahigh-performance liquid chromatography-electrospray ionisation-tandem mass spectrometry (UHPLC-ESI-MS/MS) were organic content, buffer strength, pH modifier, flow rate, spray voltage, sheath gas, and auxiliary gas that alter critical analytical attributes, such as retention time (R1) and area (R2). These factors were evaluated first in a factorial design (Taguchi orthogonal array design) and then extensively in a central composite design (CCD) to zero-in on the mobile phase for the quantification of ENZ standard drug and along with its internal standard (ENZIS) in spiked plasma samples and in formulation. Pareto chart from initial factorial design (Taguchi orthogonal array design) model suggested which of the CPA factors should be given the weightage, that is, to be exhaustively analysed in the CCD and response surface analysis. The elaborated parameters proposed by World Health Organization were studied by method validation, ie, selectivity, linearity, accuracy, precision repeatability system-suitability tests, method robustness/ruggedness, sensitivity, and stability. The strategy followed gives an insight on the development of a robust QbD-compliant quantitative UHPLC-ESI-MS/MS method for ENZ drug containing plasma samples (spiked).
08 28 2017 01 01 2017 117739011772677 10.1177/1177390117726776 2 10.1177/sage-journals-update-policy journals.sagepub.com true http://journals.sagepub.com/page/policies/text-and-data-mining-license 10.1177/1177390117726776 http://journals.sagepub.com/doi/10.1177/1177390117726776 http://journals.sagepub.com/doi/pdf/10.1177/1177390117726776 http://journals.sagepub.com/doi/pdf/10.1177/1177390117726776 http://journals.sagepub.com/doi/full-xml/10.1177/1177390117726776 10.1016/0169-7439(92)80036-4 Acta Chromatogr Sivakumar T 29 19 2007 10.1002/bmc.3613 10.4155/bio.13.325 10.1530/ERC-16-0068 10.1007/s40262-015-0283-1 10.1016/j.chroma.2014.03.077 10.1517/17460441.2014.918947 10.1007/s12272-015-0592-9 10.1016/j.jpba.2016.03.031 10.1016/j.jpba.2016.08.036 10.1007/s13318-016-0374-x 10.15583/jpchrom.2015.029 10.1093/chromsci/bmw090 10.1016/j.arabjc.2014.01.025 10.1002/bmc.3127 10.1016/j.jsbmb.2013.06.014 10.1016/S0731-7085(03)00187-0